Quantcast

Latest Lymphocytic Leukemia Stories

2014-04-08 08:31:34

SUNNYVALE, Calif., April 8, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA), based on data from the randomized, multi-center, open-label Phase III RESONATE(TM) study, PCYC-1112, a head-to-head comparison of single agent IMBRUVICA(TM) (ibrutinib) versus ofatumumab in 391 patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who...

2014-04-03 12:30:19

LONDON, April 3, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - (Pipeline Forecast & Market Forecast in G8 Countries) (2011 - 2020) The acute lymphocytic/lymphoblastic leukemia therapeutics market has growth potential as the incidence rate of the disease is increasing all over the globe. The incidence of acute lymphocytic/lymphoblastic leukemia is higher in children from 0 to 14...

2014-03-12 23:22:21

Acute Lymphocytic Leukemia Therapeutics Market report categorizes the market in G8 countries into the following segments by Drug and by Geography. http://www.marketsandmarkets.com/Market-Reports/acute-lymphocytic-leukemia-therapeutics-market-518.html (PRWEB) March 12, 2014 The “Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - (Pipeline Forecast & Market Forecast in G8 Countries) (2010 - 2020)” analyzes and studies the major market drivers, restraints, and...

2014-03-11 08:32:04

NEWTOWN, Pa., March 11, 2014 /PRNewswire/ -- BioClinica®, Inc., a leading provider of specialized outsourced clinical trial services, today announced that its technology was utilized by Pharmacyclics, Inc. (NASDAQ: PCYC) and supported the accelerated approval of IMBRUVICA(TM) (ibrutinib) for Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL). http://photos.prnewswire.com/prnvar/20130403/PH87647LOGO The Phase III clinical program supporting IMBRUVICA's early approval...

2014-03-06 23:22:54

Over the last decade, much knowledge has been gained regarding the genetic events that drive leukemia; the exact cell of origin, however, remains largely unknown. This study suggests that there may be subsets of cells at increased risk of developing leukemia. (PRWEB) March 06, 2014 Researchers at the University of Virginia School of Medicine have discovered a specific type of immune cell in the bone marrow of mice responsible for an aggressive, poorly understood form of leukemia. The...

2014-02-27 18:40:45

A study led by Dr. Roderic Guigó from the Centre for Genomic Regulation in Barcelona, as part of the Chronic Lymphatic Leukaemia Genome Consortium, has made new advances in the study of this disease. The work, which was published (in print version) last week in the journal Genome Research, scrutinized the functional profile of the genes and mutations associated with leukemia. The Spanish Chronic Lymphatic Leukaemia Genome Consortium had previously identified the principal mutations...

2014-02-20 12:02:02

Babies who develop leukemia during the first year of life appear to inherit an unfortunate combination of genetic variations that can make the infants highly susceptible to the disease, according to a new study at Washington University School of Medicine in St. Louis and the University of Minnesota. The research is available online in the journal Leukemia. Doctors have long puzzled over why it is that babies just a few months old sometimes develop cancer. As infants, they have not lived...

2014-02-13 12:27:27

FLINT, Mich., Feb. 13, 2014 /PRNewswire-iReach/ -- Diplomat, the country's largest independent specialty pharmacy, announced today that IMBRUVICA(TM) (ibrutinib) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of chronic lymphocytic lymphoma (CLL) in patients who have received at least one prior therapy. An improvement in survival or disease-related symptoms has not been established. IMBRUVICA(TM), a Bruton's tyrosine kinase (BTK) inhibitor, is an oral...

2014-02-12 16:25:59

HORSHAM, Pa., Feb. 12, 2014 /PRNewswire/ -- Janssen Biotech, Inc. ["Janssen"] today announced the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA(TM) (ibrutinib) capsules for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.(1) IMBRUVICA was first approved in November 2013 for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.(1) Both indications are based...

2014-02-12 12:32:40

SUNNYVALE, Calif., Feb. 12, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA((TM)) (ibrutinib) as a single agent for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.(1) This indication is based on overall response rate (ORR). An improvement in survival or disease-related symptoms has not been established.(1) IMBRUVICA is the first...


Word of the Day
ramage
  • Boughs or branches.
  • Warbling of birds in trees.
Related